Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of 23-valent Pneumococcal Polysaccharide Vaccine in Healthy Population
NCT02451969Phase 3Completed
- Sponsor
- Sinovac Biotech Ltd.
- Start
- Apr 2015
- Primary completion
- Jun 2015
- Modality
- Split/Subunit Vaccines
- Countries
- 1
01
Overview
A Phase 3 trial of Sinovac 23-valent pneumococcal polysaccharide vaccine in pneumococcal infection, sponsored by Sinovac Biotech Ltd.. Started Apr 2015; status: completed.
02
Drugs
Sinovac 23-valent pneumococcal polysaccharide vaccine
03
Conditions
pneumococcal infection
Beyond the preview
Go deeper on NCT02451969.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02451969.